Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-08
2007-05-08
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S221000, C514S259100, C544S279000, C544S281000
Reexamination Certificate
active
10490135
ABSTRACT:
The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a hydroxyiminomethylene group, a dioxolan group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring optionally substituted; R2 may represent a C1-6alkyl group optionally; a C3-6cycloalkyl group, a C1-4alkythio group, a C1-4alkoxy group, a C1-2perhalogenated alkyl group, a C1-3halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represent, each independently, a hydrogen atom, a C1-6alkyl group, a hydroxy group, a C1-4alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6alkyl group or a halogen atom; with the proviso that when R3 and R4 represent each a hydrogen atom then R5 is not a hydrogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β, and cdk5/p25, such as Alzheimer disease
REFERENCES:
patent: 6974819 (2005-12-01), Garcia et al.
patent: WO 98/16528 (1998-04-01), None
patent: WO 98/24780 (1998-06-01), None
patent: WO 99/65897 (1999-12-01), None
patent: WO 00/18758 (2000-04-01), None
patent: WO 01/42224 (2001-06-01), None
patent: WO 01/44246 (2001-06-01), None
Leclerc, et al. (“Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease,” The Journal of Biological Chemistry, 276, No. 1, Jan. 2, 2001, pp. 251-260).
Bhat, et al. (“Glycogen Synthase Kinase 3: A Drug Target for CNS Therapies,” Journal of Neurochemistry, 2004, 89, 1313-1317).
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-221 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Derivative (chemistry), retriieved from “http://en.wikipedia.org/wiki/Derivative-%28chemistry%29” on Aug. 10, 2006.
List of neurodegenerative diseases; from the University of California, Nov. 2006.
List of neurodegenerative diseases; from Wikipedia, Nov. 2006.
Harwood, PubMed abstract of Curr. Mol. Med., Aug. 2003; 3(5): 472-82.
Gallet Thierry
Lardenois Patrick
Lochead Alistair
Marguerie Séverine
Nedelec Alain
Gupta Balaram
Jaisle Cecilia
Mitsubishi Pharma Corporation
Rao Deepak
Sanofi-aventis
LandOfFree
Substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3802864